🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Pharma Mar SAU (PHMR)

Madrid
Currency in EUR
77.050
-1.800(-2.28%)
Delayed Data
PHMR Scorecard
Full Analysis
Impressive gross profit margins
Fair Value
Day's Range
76.30078.850
52 wk Range
26.16086.400
Key Statistics
Edit
Bid/Ask
76.75 / 77.05
Prev. Close
78.85
Open
77.05
Day's Range
76.3-78.85
52 wk Range
26.16-86.4
Volume
16.16K
Average Volume (3m)
83.32K
1-Year Change
100.64%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHMR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
83.200
Upside
+7.982%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Pharma Mar SAU Company Profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Employees
509
Market
Spain

Compare PHMR to Peers and Sector

Metrics to compare
PHMR
Peers
Sector
Relationship
P/E Ratio
2,223.4x5.1x−0.7x
PEG Ratio
-0.210.00
Price/Book
7.6x2.3x2.6x
Price / LTM Sales
8.3x3.8x3.2x
Upside (Analyst Target)
7.8%56.9%47.1%
Fair Value Upside
Unlock14.1%7.3%Unlock

Analysts' Recommendations

2 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 83.200

(+7.98% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.035
Dividend Yield
-
Annualized payout
-
5-Years Growth
-
Growth Streak

People Also Watch

29.42
LOG
-0.47%
9.610
BBVA
+0.19%
3.124
SCYR
-0.26%
1.321
UNI
+0.15%
8.865
GRLS
-0.06%

FAQ

What Is the Pharma Mar (PHMR) Stock Price Today?

The Pharma Mar stock price today is 77.05

What Stock Exchange Does Pharma Mar Trade On?

Pharma Mar is listed and trades on the Madrid stock exchange.

What Is the Stock Symbol for Pharma Mar?

The stock symbol for Pharma Mar is "PHMR."

Does Pharma Mar Pay Dividends? What’s The Current Dividend Yield?

The Pharma Mar dividend yield is 0.82%.

What Is the Pharma Mar Market Cap?

As of today, Pharma Mar market cap is 1.35B.

What is Pharma Mar Earnings Per Share?

The Pharma Mar EPS is 0.035.

What Is the Next Pharma Mar Earnings Date?

Pharma Mar will release its next earnings report on Mar 02, 2025.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.